Trials to slow progression and prevent disease onset
Current treatments for Alzheimer’s disease (AD) are largely symptomatic and improve cognition. Only a single trial of selegiline and vitamin E has been demonstrated to delay progression of the time to clinically important endpoints in this disease. Effective treatments currently under development are designed to either slow the rate of progression or delay the time of onset. Classes of agents currently being investigated include: antioxidants, anti-inflammatory agents, growth factors, hormones, and drugs designed to prevent the deposition or enhance the removal of amyloid. In addition to trials designed to slow the rate of progression, several primary prevention trials have already been initiated. Finally, a series of trials designed to prevent the development of AD in patients with mild cognitive impairment have been initiated.
KeywordsNerve Growth Factor Mild Cognitive Impairment Alzheimer Type Primary Prevention Trial Ginkgo Biloba Extract
Unable to display preview. Download preview PDF.
- Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas PG, Weiner MF, Farlow MR, Sano M, Grundman M, Thai LJ (for the Members of the Alzheimer’s Disease Cooperative Study) (2000) A randomized controlled trial of prednisone in Alzheimer’s disease. Neurology 54: 588 – 593Google Scholar
- Behl C, Davis J, Cole GM, et al (1992) Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 186: 944 – 950Google Scholar
- Freedman M, Rewilak D, Xerri T, et. al. (1998) L-deprenyl in Alzheimer’s diseaseGoogle Scholar
- Cognitive and behavioral effects. Neurology 50: 660–668Google Scholar
- Glasky AJ, Ritzmann RF, Prisecaru I, et al (1996) Elevation of brain mRNA for neurotrophins by oral AIT-082 in mice. Soc Neurosci 22: 751 Halliwell B, Gutteridge JMC (1985) Oxygen radicals in the nervous system. Trends Neurosci 8: 22 – 26Google Scholar
- Hefti F (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 14: 2155 – 2162Google Scholar
- Honjo H, Ogino Y, Naitoh K, et al (1989) In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer’s type). J Steroid Biochem Mol Biol 34: 521 – 525Google Scholar
- Ohkura T, Isse K, Akazawa K, et al (1994) Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrinology J 41: 361 – 371Google Scholar
- Packer L, Haramaki N, Kawabata T, et al (1995) Ginkgo biloba extract (EGb 761). In: Christen Y, Courtois Y, Droy-Lefaix MT (eds), Effect of Ginkgo Biloba extract (EGb 761 ) on aging and age-related disorders. Elsevier, Paris: 23 – 47Google Scholar
- Thai LJ, Carta A, Clarke WR, et al (1996) A one-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer’s disease. Neurology 47: 705 – 711Google Scholar